Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

APT Medical Closes $191 Million Shanghai STAR Board IPO

publication date: Jan 7, 2021

APT Medical completed a $191 million IPO on the Shanghai STAR Exchange, rising 245% in its first trading session to a market cap of $2.7 billion. Founded in 2002, the company makes a variety of affordable catheters for cardiovascular conditions. Its offerings include coronary artery access and electrophysiological products, plus peripheral blood vessels and nerve intervention medical products. APT claims to have the largest China market share among domestic electrophysiological medical device companies. Qiming Ventures was an early investor with a 19% stake in the company after the IPO. More details....

Stock Symbol: (SHA: 688617)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021